Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Placebo 40 mg

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,919 result(s) found for: Placebo 40 mg. Displaying page 89 of 196.
    «« First « Previous 85  86  87  88  89  90  91  92  93  Next» Last»»
    EudraCT Number: 2020-005407-38 Sponsor Protocol Number: MK-3475-B49 Start Date*: 2021-08-17
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positi...
    Medical condition: Treatment of patients with HR+/HER2- locally recurrent inoperable or MBC whose tumors express PD-L1
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-007198-21 Sponsor Protocol Number: H9X-MC-GBCF Start Date*: Information not available in EudraCT
    Sponsor Name:Eli Lilly and Company - Indianapolis
    Full Title: A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients with Type 2 Diabetes Mellitus on Metformin
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001037-41 Sponsor Protocol Number: RPL554-CO-204 Start Date*: 2018-09-04
    Sponsor Name:Verona Pharma plc
    Full Title: A PHASE II, RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, THREE WAY CROSSOVER STUDY TO ASSESS THE BRONCHODILATOR EFFECT OF RPL554 ADMINISTERED IN ADDITION TO OPEN LABEL TIOTROPIUM/OLODATEROL IN PAT...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004574-17 Sponsor Protocol Number: CC-220-SLE-002 Start Date*: 2017-06-08
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
    Medical condition: SYSTEMIC LUPUS ERYTHEMATOSUS
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004859 10025134 Lupus erythematosus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Completed) DE (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-003351-11 Sponsor Protocol Number: 20120141 Start Date*: 2013-03-08
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Inadequately Controlled Asthma and High Bronchodilator Reversibility
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10003561 Asthma, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IE (Prematurely Ended) IT (Completed) GR (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004450-15 Sponsor Protocol Number: RPL554-CO-202 Start Date*: 2017-01-27
    Sponsor Name:Verona Pharma plc
    Full Title: A phase II, randomised, double blind, placebo controlled, three way crossover study to assess the bronchodilator effect of RPL554 administered in addition to open label tiotropium in patients with ...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002068-26 Sponsor Protocol Number: BEL115123 Start Date*: 2011-11-24
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Belimumab in Subjects with Generalized Myasthenia Gravis (MG).
    Medical condition: Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001890-42 Sponsor Protocol Number: CLHW090X2202 Start Date*: 2016-04-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, sponsor open, site and subject double-blind, parallel group, placebo-controlled study to evaluate the safety and efficacy of LHW090 after 4 weeks treatment in patients with resistant ...
    Medical condition: Resistant hypertension
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10015491 Essential hypertension, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) DK (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002106-36 Sponsor Protocol Number: JNJ-DEP Start Date*: 2016-01-11
    Sponsor Name:Clinirx Tangent Research
    Full Title: The effects of JNJ-39393406 on psychometric performance and residual depressive symptoms in 80 patients with unipolar or bipolar depression: a phase II exploratory add-on double blind placebo contr...
    Medical condition: Unipolar and bipolar depression
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004873 10004936 Bipolar depression LLT
    19.0 100000004873 10045543 Unipolar depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: RO (Suspended by CA)
    Trial results: (No results available)
    EudraCT Number: 2019-004998-34 Sponsor Protocol Number: B-2660-203 Start Date*: 2020-07-16
    Sponsor Name:Blade Therapeutics, Inc.
    Full Title: A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacodynamics, Pharmacokinetics, and Safety of BLD-2660 Administered Orally in Subjects with Idiopathic Pulmonary Fibrosis
    Medical condition: Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003402-25 Sponsor Protocol Number: OCT-UKE-2011 Start Date*: 2011-12-13
    Sponsor Name:Schülke & Mayr GmbH
    Full Title: Randomized, Double-blind, Single-center, Placebo-controlled Study to evaluate the Efficacy of octenisept® in Patients with Chronic Wounds.
    Medical condition: Chronic leg ulcers
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10068310 Leg ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000179-38 Sponsor Protocol Number: ESR-21-21168 Start Date*: 2022-04-28
    Sponsor Name:Bispebjerg Hospital
    Full Title: Effects of blocking TSLP on airway inflammation and the epithelial immune-response to exacerbation triggers in patients with COPD A randomized double-blind, placebo-controlled trial of tezepelumab
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10009032 Chronic obstructive lung disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003648-97 Sponsor Protocol Number: CLI-06001AA1-05 Start Date*: 2021-05-17
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A 52-week, randomized, double-blind, double-dummy, placebo- and active- controlled (Roflumilast, Daliresp® 500μg), parallel group, study to evaluate the efficacy and safety of two doses of CHF6001 ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) EE (Trial now transitioned) LV (Trial now transitioned) ES (Ongoing) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000187-42 Sponsor Protocol Number: 156-12-298 Start Date*: 2016-10-24
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3b, Two-part, Multicenter, One Year Randomized, Double-blind, Placebo-controlled Trial of the Safety, Pharmacokinetics, Tolerability, and Efficacy of Tolvaptan followed by a Two Year Open-l...
    Medical condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000720-18 Sponsor Protocol Number: CNTO1959PSO3002 Start Date*: 2015-02-11
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Seve...
    Medical condition: Moderate to Severe Plaque Type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-004287-23 Sponsor Protocol Number: P04592 Start Date*: 2006-12-05
    Sponsor Name:Schering Plough Research Institute, a division of Schering Corporation
    Full Title: Safety and Dose-Ranging Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006422-33 Sponsor Protocol Number: ASAC-ANADA-1-08 Start Date*: 2009-07-22
    Sponsor Name:Especialidades Farmacéuticas Centrum, S.A
    Full Title: Ensayo clínico, aleatorizado, doble ciego, controlado con placebo, de la eficacia de Anapsos® en la reducción del empleo de corticosteroides tópicos en el tratamiento de la dermatitis atópica moder...
    Medical condition: Pacientes diagnosticados de dermatitis atópica según los criterios de Hanifin y Rajka, con índice SCORAD de 20 a 40, ambos inclusive, que utilicen o en quienes se indique el empleo de corticosteroi...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012438 Dermatitis atopic LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004974-94 Sponsor Protocol Number: 74460 Start Date*: 2005-02-09
    Sponsor Name:Santen Oy
    Full Title: Efficacy and safety of tafluprost 0.0015% eye drops as adjunctive therapy with timolol 0.5% eye drops. A randomised, placebo-controlled, phase III study in patients with open-angle glaucoma or ocul...
    Medical condition: Open angle glaucoma or ocular hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2007-000947-88 Sponsor Protocol Number: 09A502 Start Date*: 2008-02-18
    Sponsor Name:ISTITUTO AUXOLOGICO ITALIANO
    Full Title: Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects with Metabolic Syndrome and High-Normal Blood Pressure.
    Medical condition: Hypertension, diabetes mellitus.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10007541 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005278-12 Sponsor Protocol Number: BAY1019036/15082 Start Date*: 2015-02-09
    Sponsor Name:Bayer HealthCare AG
    Full Title: A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Trial Assessing the Analgesic Efficacy of a Single, Oral Dose of a Fast Release Aspirin 650 mg in Postsurgical Dental Pain
    Medical condition: postsurgical (extraction) dental pain
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004856 10044049 Dental pain and sensation disorders HLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 85  86  87  88  89  90  91  92  93  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 09:31:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA